Surmodics, Inc. (SRDX)
Market Cap | 598.55M |
Revenue (ttm) | 142.96M |
Net Income (ttm) | 13.50M |
Shares Out | 14.26M |
EPS (ttm) | 0.96 |
PE Ratio | 43.72 |
Forward PE | 81.97 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 161,699 |
Open | 41.93 |
Previous Close | 41.90 |
Day's Range | 41.86 - 41.99 |
52-Week Range | 25.17 - 42.36 |
Beta | 1.18 |
Analysts | Hold |
Price Target | 43.00 (+2.45%) |
Earnings Date | Jul 31, 2024 |
About SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating... [Read more]
Financial Performance
In 2023, Surmodics's revenue was $132.58 million, an increase of 32.65% compared to the previous year's $99.95 million. Losses were -$1.54 million, -94.37% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43.0, which is an increase of 2.45% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/5/press10-2470653.jpg)
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing ...
![](https://cdn.snapi.dev/images/v1/r/b/press19-2455478.jpg)
SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
![](https://cdn.snapi.dev/images/v1/o/l/press20-2452791.jpg)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquis...
![](https://cdn.snapi.dev/images/v1/z/u/press3-2451891.jpg)
Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click her...
![](https://cdn.snapi.dev/images/v1/f/d/press1-2451480.jpg)
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics ...
![](https://cdn.snapi.dev/images/v1/c/v/press16-2451208.jpg)
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered ...
![](https://cdn.snapi.dev/images/v1/g/3/press1-2402250.jpg)
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today report...
![](https://cdn.snapi.dev/images/v1/k/y/conf10-2380277.jpg)
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announ...
![](https://cdn.snapi.dev/images/v1/g/0/conf18-2295647.jpg)
Surmodics to Participate in Upcoming Investor Conferences in March and April
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...
![](https://cdn.snapi.dev/images/v1/d/t/press3-2255022.jpg)
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
![](https://cdn.snapi.dev/images/v1/6/l/press17-2238065.jpg)
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the co...
![](https://cdn.snapi.dev/images/v1/d/k/press19-2230183.jpg)
Surmodics to Host Virtual Annual Meeting of Shareholders
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting...
![](https://cdn.snapi.dev/images/v1/9/e/conf2-2230184.jpg)
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first q...
![](https://cdn.snapi.dev/images/v1/l/3/press17-2161082.jpg)
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...
![](https://cdn.snapi.dev/images/v1/r/l/press14-2161080.jpg)
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-mont...
![](https://cdn.snapi.dev/images/v1/n/q/press13-2157964.jpg)
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...
![](https://cdn.snapi.dev/images/v1/0/w/press5-2146558.jpg)
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
![](https://cdn.snapi.dev/images/v1/p/0/press16-2143683.jpg)
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Profess...
![](https://cdn.snapi.dev/images/v1/p/d/press17-2143686.jpg)
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...
![](https://cdn.snapi.dev/images/v1/j/j/press8-2129986.jpg)
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical...
![](https://cdn.snapi.dev/images/v1/i/x/conf1-2096482.jpg)
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth ...
![](https://cdn.snapi.dev/images/v1/i/m/conf4-2015926.jpg)
Surmodics to Participate in Upcoming Investor Conferences in August
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.
![](https://cdn.snapi.dev/images/v1/k/d/press19-2001095.jpg)
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
![](https://cdn.snapi.dev/images/v1/r/b/conf6-1967710.jpg)
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #August22023--Surmodics, Inc. (SRDX) announces third quarter of fiscal year 2023 financial results will be released on Wednesday, August 2.
![](https://cdn.snapi.dev/images/v1/n/e/press17-1939888.jpg)
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Angioplasty--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announc...